Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: Current status and future opportunities

被引:27
作者
Conlin, Alison K. [1 ]
Seidman, Andrew D. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
关键词
bevacizumab; ixabepilone; microvessel density; sunitinib;
D O I
10.3816/CBC.2008.n.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As reflected In its varied clinical behavior, appearances under the light microscope, and differential patterns of gene expression, metastatic breast cancer (MBC) is a heterogeneous disease. Systemic treatment decisions are guided by specific tumor characteristics and individual patient factors. For patients with hormone therapies, cytotoxic chemotherapy has been the mainstay of systemic treatment. For hormone-insensitive, HER2-positive MBCs, the addition of trastuzumab to chemotherapy has resulted in improved outcomes. Hormone-insensitive MBC lacking HER2 overexpression includes the subset of patients with estrogen receptor/progesterone receptor/HER2-negative (so-called triple-negative) disease, which represents a significant minority of all breast cancers. Therapeutic options for such patients are limited by the lack of specific targeted approaches, and this heterogeneous group will be considered collectively as well as separately in this overview of existing and emerging treatment strategies. Conventional cytotoxic chemotherapy, alone or in combination, has been the standard first-line treatment for patients with MBC not amenable to antiestrogen or trastuzumab therapy. The recent evaluation of new targeted therapies in combination with cytotoxic agents has created a new type of combination regimen. Agents targeting angiogenesis, the epidermal growth factor receptor, and various signal transduction pathways have been combined with chemotherapy and possess biologic activity in MBC. As these combinations are being investigated, parallel correlative studies aimed at enriching the population who will benefit most are under way.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 73 条
  • [61] Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)
    Sledge, GW
    Neuberg, D
    Bernardo, P
    Ingle, JN
    Martino, S
    Rowinsky, EK
    Wood, WC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 588 - 592
  • [62] Trends in breast cancer by race and ethnicity: Update 2006
    Smigal, C
    Jemal, A
    Ward, E
    Cokkinides, V
    Smith, R
    Howe, HL
    Thun, M
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (03) : 168 - 183
  • [63] Repeated observation of breast tumor subtypes in independent gene expression data sets
    Sorlie, T
    Tibshirani, R
    Parker, J
    Hastie, T
    Marron, JS
    Nobel, A
    Deng, S
    Johnsen, H
    Pesich, R
    Geisler, S
    Demeter, J
    Perou, CM
    Lonning, PE
    Brown, PO
    Borresen-Dale, AL
    Botstein, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) : 8418 - 8423
  • [64] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    Sorlie, T
    Perou, CM
    Tibshirani, R
    Aas, T
    Geisler, S
    Johnsen, H
    Hastie, T
    Eisen, MB
    van de Rijn, M
    Jeffrey, SS
    Thorsen, T
    Quist, H
    Matese, JC
    Brown, PO
    Botstein, D
    Lonning, PE
    Borresen-Dale, AL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10869 - 10874
  • [65] Breast cancer classification and prognosis based on gene expression profiles from a population-based study
    Sotiriou, C
    Neo, SY
    McShane, LM
    Korn, EL
    Long, PM
    Jazaeri, A
    Martiat, P
    Fox, SB
    Harris, AL
    Liu, ET
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) : 10393 - 10398
  • [66] Tang J, 2006, BREAST CANCER RES TR, V100, pS243
  • [67] Thomas ES, 2007, J CLIN ONCOL, V25, P5210, DOI 10.1200/JCO.2007.12.6557
  • [68] Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis
    Uzzan, B
    Nicolas, P
    Cucherat, M
    Perret, GY
    [J]. CANCER RESEARCH, 2004, 64 (09) : 2941 - 2955
  • [69] Gene expression profiling predicts clinical outcome of breast cancer
    van't Veer, LJ
    Dai, HY
    van de Vijver, MJ
    He, YDD
    Hart, AAM
    Mao, M
    Peterse, HL
    van der Kooy, K
    Marton, MJ
    Witteveen, AT
    Schreiber, GJ
    Kerkhoven, RM
    Roberts, C
    Linsley, PS
    Bernards, R
    Friend, SH
    [J]. NATURE, 2002, 415 (6871) : 530 - 536
  • [70] Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer -: Final results of a dose-finding and efficacy study
    Viens, P
    Roché, H
    Kerbrat, P
    Fumoleau, P
    Guastalla, JP
    Delozier, T
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (04): : 328 - 335